Scoring system for clinically significant cmv infection in seropositive recipients following allogenic hematopoietic cell transplant: an sfgm-tc study - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplant Année : 2020

Scoring system for clinically significant cmv infection in seropositive recipients following allogenic hematopoietic cell transplant: an sfgm-tc study

Didier Blaise
  • Fonction : Auteur
Régis Peffault de Latour
  • Fonction : Auteur
Edouard Forcade
  • Fonction : Auteur
Patrice Ceballos
  • Fonction : Auteur
Anne Uyttebroeck
  • Fonction : Auteur
Helene Labussiere
  • Fonction : Auteur
Stéphanie Nguyen-Quoc
  • Fonction : Auteur
Jean-Henri Bourhis
  • Fonction : Auteur
Patrice Chevallier
  • Fonction : Auteur
Anne Thiebaut
  • Fonction : Auteur
Xavier Poire
  • Fonction : Auteur
Sébastien Maury
  • Fonction : Auteur
Eric Deconinck
  • Fonction : Auteur
Thomas Cluzeau
  • Fonction : Auteur
Eolia Brissot
Anne Huynh
  • Fonction : Auteur
Marie-Thérèse Rubio
  • Fonction : Auteur

Résumé

In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patients were chronologically divided into a derivation cohort (2010-2012, n = 2180) and a validation cohort (2013-2014, n = 1490). Haploidentical donors were excluded. The incidence of first clinically significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) at 1, 3, and 6 months in the derivation cohort was 13.8%, 38.5%, and 39.6%, respectively. CMV-seropositive donor, unrelated donor (HLA matched 10/10 or HLA mismatched 9/10), myeloablative conditioning, total body irradiation, antithymocyte globulin, and mycophenolate mofetil significantly and independently affected the incidence of 3-month infection. These six factors were selected to build up the prognostic model. Four risk groups were defined: low, intermediate-low, intermediate-high, and high-risk categories, with a 3-month predicted incidence of first clinically significant CMV infection in the derivation cohort of 22.2%, 31.1%, 45.4%, and 56.9%, respectively. This score represents a framework for the evaluation of patients who are at risk of developing clinically significant CMV infection following allo-HCT. Prospective studies using this score may be of benefit in assessing the value of anti-CMV prophylaxis in well-defined patient cohorts.
Fichier non déposé

Dates et versions

hal-04512720 , version 1 (20-03-2024)

Identifiants

Citer

David Beauvais, Elodie Drumez, Didier Blaise, Régis Peffault de Latour, Edouard Forcade, et al.. Scoring system for clinically significant cmv infection in seropositive recipients following allogenic hematopoietic cell transplant: an sfgm-tc study. Bone Marrow Transplant, 2020, Bone marrow transplantation, 56, pp.1305-1315. ⟨10.1038/s41409-020-01178-6⟩. ⟨hal-04512720⟩

Collections

RIIP UNIV-LILLE
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More